Holen Sie sich die Stockscreener-App
0.2616
0.08%
0.0002
Vorhandelsmarkt:
.28
0.0184
+7.03%
Ensysce Biosciences Inc Aktie (ENSC) Neueste Nachrichten
Ensysce Biosciences Inc (ENSC) Cash Flow - TradingKey
ENSC|Ensysce Biosciences Inc|Price:0.255|Chg%:-0.006 - TradingKey
TradingKey - TradingKey
Ensysce Biosciences Inc (ENSC) Institutional Confidence - TradingKey
Ensysce Biosciences Inc (ENSC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ensysce Biosciences Inc (ENSC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ensysce Biosciences Inc (ENSC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ENSC News | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Ensysce Biosciences COO Jeffrey Millard resigns effective July 10, 2026 - TradingView
COO Jeffrey Millard exits Ensysce Biosciences (Nasdaq: ENSC) July 10 - Stock Titan
Ensysce Biosciences, Inc. Announces Resignation of Jeffrey Millard as Chief Operating Officer, Effective July 10, 2026 - marketscreener.com
Ensysce receives $5.3M NIDA award for opioid overdose therapy By Investing.com - Investing.com Nigeria
Ensysce receives $5.3M NIDA award for opioid overdose therapy - Investing.com
Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant - Weatherford Democrat
Federal funds back Ensysce opioid technology designed to limit overdose - Stock Titan
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth - Yahoo Finance Singapore
Ensysce Biosciences (ENSC) Edges Higher: Key Support Holds as Volume Picks UpProfitability Factor - dars.gov.et
Ensysce Biosciences, Inc. Financial Disclosures & SEC Filings - TradingView
12 Health Care Stocks Moving In Thursday's After-Market SessionSeer (NASDAQ:SEER), Universe Pharmaceut - Benzinga
Price to sales forward of Ensysce Biosciences, Inc. – NASDAQ:ENSC - TradingView
Enterprise value to revenue forward of Ensysce Biosciences, Inc. – NASDAQ:ENSC - TradingView
Price to earnings forward of Ensysce Biosciences, Inc. – NASDAQ:ENSC - TradingView
Price to book forward of Ensysce Biosciences, Inc. – NASDAQ:ENSC - TradingView
Enterprise value to EBITDA forward of Ensysce Biosciences, Inc. – NASDAQ:ENSC - TradingView
[EFFECT] Ensysce Biosciences, Inc. SEC Filing - Stock Titan
Ensysce initiates final stage of opioid overdose protection study By Investing.com - Investing.com Nigeria
Ensysce Biosciences enrolls first patient in final stage of PF614-MPAR-102 study - grafa.com
Ensysce initiates final stage of opioid overdose protection study - Investing.com
Ensysce starts final PF614-MPAR study stage for overdose-protection opioid - Stock Titan
Ensysce Biosciences, Inc. Actuals & Estimates (NASDAQ:ENSC) - TradingView
ENSC Should I Buy - Intellectia AI
Ensysce Biosciences Inc (ENSC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ENSYSCE BIOSCIENCES INC (ENSC) Stock Chart - ChartMill
Ensysce Biosciences Inc (ENSC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ensysce Biosciences Inc (ENSC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ensysce Biosciences Inc (ENSC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ensysce Biosciences Slips 3.94% as Stock Tests Key Support at $0.23New Listing Stocks - newsline.com
ENSC Q1 2026 Earnings: Narrowing Losses Signal Progress Amid Market VolatilityEarnings Acceleration Picks - lwvtexas.org
Ensysce Biosciences Files for Sale of 1.3 Million Shares - Moomoo
Ensysce Biosciences (NASDAQ: ENSC) registers up to 1.3M shares for resale - Stock Titan
ENSC Q1 2026 Earnings: Narrower-Than-Expected Loss Despite No RevenueEarnings Whisper Number - The Legal Advocate
ENSC Q1 2026 Earnings: Narrower-than-expected loss boosts sharesMargin Guidance - newsline.com
Ensysce Biosciences (ENSC) Drops 3% as Stock Nears Support at $0.28MA Crossover - The Legal Advocate
Ensysce Biosciences (ENSC) Declines Further, Tests Key Support Near $0.29Diamond Pattern - Newser
ENSCEnsysce Biosciences Inc Stock Price and Quote - Finviz
Ensysce Faces New Nasdaq Issue as Deadline Nears - Bez Kabli
ENSC Q1 2026 Earnings: Narrower-than-expected Net Loss as EPS Beats EstimatesSegment Revenue Breakdown - The Legal Advocate
Ensysce Biosciences, Inc. Files Form 8-K: Company Details, Nasdaq Listing, and Compliance Update - Minichart
Ensysce Biosciences receives Nasdaq notice for non-compliance with equity rule - Investing.com
Ensysce Biosciences Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Ensysce Biosciences (NASDAQ: ENSC) warned on Nasdaq equity listing rule - Stock Titan
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases - Yahoo Finance
Ensysce Biosciences : Corporate Overview - marketscreener.com
ENSC Advancing Testing and Expanding Potential - Yahoo Finance
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):